1. Introduction

Over the last few years our understanding of the role of platelets has evolved. While originally considered to be solely involved in thrombus formation recent studies suggest that they play an important role in the innate immune system. As the most numerous particles in the blood platelets are the first responders to any breaches in the vasculature where they bind to the damaged vessel and aggregate to seal the leak. They also become activated and secrete the contents of their granules, which contain anti-microbial peptides, which acts to sterilise the wound and to recruit other immune cells. As a result thrombocytopenia is a common response to infection by many different organisms [1, 2].

As part of the innate immune system platelets express many different pathogen recognition molecules that are involved in immune function rather than thrombosis. Thus platelets express Toll-Like Receptors (TLRs), which are pathogen recognition receptors [3] and in particular platelet TLR2 [4], TLR4 [5] and TLR7 [6] have been shown to be functional. Another important immune receptor is FcγRIIa, a receptor for the Fc-portion of IgG, which is typically expressed on phagocytic cells [7]. While platelets express functional FcγRIIa there is evidence of limited phagocytic ability for platelets [8-11]. DC-SIGN is another important pattern recognition molecule [12] that has been identified on platelets and found to be functional [13]. While both immune-mediated and haemostasis-mediated platelet activation result in activated platelets the platelet response is quite different in both cases [14].

The best-studied example of a role of platelets in infection is that with bacterial infection. While most effort has focused on Gram-positive bacteria many bacteria have been shown to activate platelets and these studies show a number of common features. The interaction of bacteria with platelets typically occurs due to direct binding to platelets, binding of a platelet-binding plasma protein to the bacteria or the secretion of a substance that activates platelets [1, 15, 16]. Typically streptococcal species such as S. sanguinis and S. gordonii bind directly to platelet GPIb.
In contrast *Staphylococcus aureus* binds fibrinogen, which in turn binds to GPIIb/IIIa on the platelet surface. *S. aureus* also produces toxins that activate platelets [17]. For the majority of bacteria that activate platelets, binding of IgG is required. This binds to FcγRIIa on the platelet surface triggering platelet activation [18].

2. Platelets in viral infection

While thrombocytopenia and in severe cases disseminated intravascular coagulation (DIC) are associated with bacterial infection this is also true for viral infection. Viral Haemorrhagic Fever (VHF) is similar to sepsis and both can be considered as forms of Systemic Inflammatory Response Syndrome (SIRS) [19, 20]. Equally thrombocytopenia is a common response to viral infections. However, it is worth noting that in some case the use of anti-viral agents may mediate the thrombocytopenia such as where neuraminidase inhibitors are associated with an immune thrombocytopenia [21] and abacavir enhances platelet activity by inhibiting guanylate cyclase [22].

2.1. Viral Haemorrhagic fever

Unlike with bacteria where virtually any species can lead to sepsis the viral equivalent (VHF) only occurs with members of 4 families of viruses known collectively as VHF viruses [20, 23].

**Flaviviruses.** These include Dengue virus (DENV) [24] and Yellow fever virus, which are transmitted by mosquitos and Omsk hemorrhagic fever virus [25] and Kyanasur Forest virus [26], which are transmitted by ticks. DENV is the most studied flavivirus due primarily to the 100 million infections per year with case fatality rates between 1-15% [27, 28]. Of these around 500,000 will progress to develop Dengue haemorrhagic fever (DHF) [27-30].

Dengue haemorrhagic fever is unusual as it typically occurs in response to a secondary infection with the primary infection producing relatively minor ‘flu-like symptoms. In fact there are 4 serotypes of DENV and it is infection with a second serotype that leads to dengue haemorrhagic fever. This suggests that the presence of anti-DENV antibodies is necessary for DHF to occur and this process is known as antibody-dependent enhancement (ADE) [31, 32].

These antibodies have been shown to enhance virus uptake and replication through an interaction with Fc receptors [32-35]. However, just as antibody binding to bacteria can trigger platelet activation it is likely that antibody binding to DENV will also activate platelets in an FcγRIIa-dependent manner. This platelet activation has been shown to lead to enhanced permeability [36]. Bone marrow infection occurs in animal models of Dengue [37], which could lead to thrombocytopenia due to impaired platelet production.

**Filoviruses.** Filoviruses are primarily represented by Ebola and Marburg viruses both of which cause a very severe VHF. The Ebola virus is transmitted by fruit bats. Very little is known about the pathogenesis of filovirus-induced VHF although, not surprisingly there is evidence of platelet activation [38, 39]. Sudan virus (SUDV) has been shown to be associated with an increase in von Willebrand factor (vWF) levels, which is associated with poor outcome as well as haemorrhagic presentation [40].
**Bunyaviruses.** This family includes the Phleboviruses (Rift Valley fever virus), Nairoviruses (Crimean-Congo Haemorrhagic fever, CCHF) and Hantaviruses (Hantaan virus). Thrombocytopenia and an increase in mean platelet volume are associated with CCHF [41]. Thrombocytopenia is a common feature of Severe fever with thrombocytopenia syndrome (a Phlebovirus infection) and is a predictor of fatal outcome [42] and direct binding to platelets was demonstrated [43]. Thrombocytopenia in Hantaan virus infection is also associated with poor outcome [44]. The use of steroids and IVIg was found to be successful in the treatment of CCHF in twelve patients [45] and as IVIg has been shown to act as an inhibitor of FcγRIIa [46] it suggests a potential role for FcγRIIa in CCHF.

**Arenaviruses.** These include the Old World Lassa fever virus and lymphocytic choriomeningitis virus (LCMV) and the New World Junin, Guanarito, Machupo and Sabia viruses [47]. Little is known about the pathogenesis on Arenavirus VHF although there is evidence that partial platelet depletion increases disease severity in LCMV infection [48-50].

### 2.2. Other viral infections

Although there is a paucity of data on the mechanisms involved thrombocytopenia is a common response to many viral infection and not just VHF. However, in general, viral-induced thrombocytopenia is either due to platelet activation leading to consumption or infection of the megakaryocytes leading to impaired platelet production.

**Viral-induced platelet activation.** Coxsackieviruses B infection is associated with thrombocytopenia and has been shown to directly infect platelets. This appears to be beneficial as thrombocytopenic mice had higher mortality rates than normal mice. Thus, platelets appear to act as a sponge mopping up virus particles [51]. Platelets have been shown to express Toll-like receptors that play a role in the response to infection. Recently TLR-7 has been shown to be functional in platelets and to trigger platelet activation in response to encephalomyocarditis virus in a mouse model [6]. Cytomegalovirus binds to platelet TLR-2 leading to platelet activation [48-50]. On the other hand platelet activation leads to secretion of CXCL4, which prevents HIV-1 infection of neighbouring T-cells [53] as well as secretion of other pro-inflammatory factors such as CD40L [54]. FcγRIIa also plays an important role in platelet activation by viruses just as happens with bacteria. Influenza A H1N1 forms immune complexes that can trigger platelet activation in a FcγRIIa-dependent manner [55]. DC-SIGN is present on the platelet surface and is implicated in the binding of HIV-1 [56] and Dengue virus [13]. In the case of HIV-1 it acts in conjunction with CLEC-2 [57]. Adenovirus Type 3 enhanced ADP-induced platelet activation [58]. Enhanced platelet activation and sequestration was found with Hepatitis B infection [59]. Co-infection of influenza H1N1 and *Staphylococcus aureus* greatly increased the chances of developing DIC [60]. SIV infection in macaques leads to thrombocytopenia [61]. The occurrence of thrombocytopenia in influenza H1N1 infection is associated with mortality [62].

**Platelet interaction with other cells.** HIV-1 infection increases platelet-monocyte interactions, which is associated with neuroinflammation [63]. Influenza infection of endothelial cells leads to activation and recruitment of platelets, which can further increase permeability and reduce platelet count [64]. HIV-1 infection leads to increased levels of platelet-derived CD40L and
platelet-monocyte aggregates. This results in monocyte activation and enhanced levels of extravasation especially in the brain microvasculature. It is proposed that this may play a role in the cognitive decline seen in AIDS [63-66]. The enhanced platelet activity seen in HIV patients can be reduced by treatment with aspirin [67]. The enhanced inflammation and endothelial cell activation seen in HIV [68] has been shown to persist even being present 12-years after anti-retroviral therapy [69]. Anti-retroviral therapy was found to reduce the thrombocytopenia that was found to re-occur if treatment was stopped. Re-starting treatment resolved the thrombocytopenia [70]. HIV-1-derived Tat has been shown to directly bind to platelets and activate them in a process dependent on CCR3 and β3-integrins [71]. SIV infection in macaques leads to increased platelet-monocyte interactions [61]. Platelets interact with neutrophil extracellular traps (NETs) and facilitate their ability to neutralise poxvirus [72]. In hepatitis there is evidence that platelets are being sequestered to the liver which may play a significant role in hepatitis-associated thrombocytopenia [73].

Effect of viruses on platelet production. In SIV, TGFβ-mediated down-regulation of thrombopoietin leads to reduced production of platelets [74]. Reduced platelet production has also been seen in Dengue-infected mice [75] and megakaryocytes have been shown to be infected by Dengue virus [76]. Platelets are involved in hepatocellular carcinoma in mice infected with hepatitis B [77] and aspirin and clopidogrel therapy reduced the incidence in infected patients [78]. Respiratory syncytial virus (RSV) is associated with a decrease in mean platelet volume (MPV) [79] as is rotavirus [80] while HIV infection is associated with an increase in MPV [81]. Infection of mice with γ-herpes virus has also been shown to induce the formation of anti-platelet antibodies, which leads to an immune thrombocytopenia [82].

Pathogen inactivation. A major problem with blood transfusions is the potential for passing on both bacterial and viral infections. This was a major cause of transmission with both HIV and Hepatitis C. As a result strategies for pathogen inactivation have been developed. One of the challenges in this area is that it is necessary to develop strategies that will be effective against known pathogens such as HIV and hepatitis C as well as pathogens that we are not aware of yet. There are two specific products that need to be treated requiring different strategies. In the case of plasma solvent-detergent treatment can be effective however, this cannot be used for cell-based products such as red blood cells or platelets [83-86].

Conclusion. The platelet response to viral infection has many of the similarities of the response to bacterial infection. The primary purpose of this is host-defence and in this context there is evidence that platelets act as sponges to absorb the viruses and subsequently being cleared from the circulation. However, thrombocytopenia can also arise from infection of the endothelium, which binds platelets and removes them from the circulation. The other cause of viral-induced thrombocytopenia is impaired platelet production in response to megakaryocyte infection. There is evidence to support all of these mechanisms with different viruses having different effects. In fact even with a single virus multiple effects on platelets can be seen just as different bacteria have different mechanisms for activating platelet [1, 16] and even individual bacteria have multiple mechanism that depend on the shear stress of the local environment [87].

While the strategy of an anti-viral sponge is effective it is not without its problems. Excessive platelet activation can lead to disseminated intravascular coagulation such as occurs in an
extreme form in VHF. Correcting this DIC is critical for survival of the patient. Equally the prolonged hyper-activity of platelets in HIV-positive patients is a risk factor for cardiovascular disease in these patients. There is some evidence that anti-platelet agents can play a role here but as they inhibit platelet activity they may not be the ideal solution especially in DIC. A better strategy is to identify the mechanisms involved in the thrombocytopenia and to develop an inhibitor of the virus-platelet interaction without compromising platelet function (Figure 1). Interestingly FcγRIIa has been found to be an important drug target in bacteria-platelet interactions [1, 16] and there is evidence that with some viruses it may also be an important drug target as well [55].

Figure 1. Virus can interact with platelets through multiple different receptors. Dengue (DENV) and Influenza H1N1 bind to FcγRIIa; HIV binds to CLEC-2; DENV and HIV can bind to DC-SIGN and Cytomegalovirus virus (CMV) and encephalomyocarditis (EMCV) bind to Toll-like receptors (TLR).

3. Parasites

As platelets are part of the innate immune system and interact with bacteria and viruses they also interact with parasites. In this context they bind to parasites and in some cases will kill them. As a result there can be a thrombocytopenia as well as evidence of micro-thrombi formation. The most studied parasites that interacts with platelets are the malaria parasites [88] although there has been some work on other parasites as well.

3.1. Malaria

Malaria is a mosquito borne parasite infection (*Plasmodium*), which is transmitted to humans through the *Anopheles* mosquito. Malaria is a major cause of morbidity and mortality in the developing world with 207 million cases of malaria in 2012 and an estimated 627 000 deaths, mostly children under five and pregnant women who live in Sub-Saharan Africa (WHO 2013). Malaria is caused by infection with *Plasmodium falciparum*, *P. vivax*, *P. ovale*, *P. malariae* or *P. knowlesi*. Most of the deaths are due to infection by *P. falciparum* as it is the most severe infection as well as the dominant infection. *P. berghei* and *P. chabaudi* infect mice and are frequently used
for animal studies. Most cases of malaria present as uncomplicated malaria with characteristic symptoms of fever, nausea and aches, however, some can present with severe malaria that involves impaired function of various organs. The most serious form of severe malaria is cerebral malaria, which is estimated to occur in 10% of hospitalised cases and is associated with 80% of deaths. Cerebral malaria occurs when infected red blood cells (RBCs) occlude cerebral blood vessels [89].

**Thrombocytopenia in malaria.** Thrombocytopenia is a common feature in malaria [90, 91]. In fact it is considered to be diagnostic in febrile patients [92, 93]. The extent of the thrombocytopenia is also a predictor of outcome [94-96]. There are a few studies suggesting that malarial thrombocytopenia is driven by platelet activation in patients with malaria [97, 98], and infected mice [99, 100]. A possible explanation for platelet activation in malaria is complement formation. The formation of C3d, indicating complement activation, was associated with thrombocytopenia in malaria-infected patients [101]. Nevertheless activation of platelets in malaria could also be related to direct interaction with the parasites [102, 103]. There is also evidence of immune-mediated clearance with two studies identifying an increased level of platelet-associated antibodies in thrombocytopenic malaria patients [104, 105]. This was further supported by a study that showed an association between polymorphisms in FcγRIIa, the platelet IgG receptor and disease severity [106]. IgE levels have also been associated with severity of malaria [107].

Platelets have been shown to be involved in clumping of parasitized red cells [108] and they have been found to accumulate in the brains of patients with cerebral malaria [108, 109].

**Plasmodium and platelet interaction.** GPIV (CD36) is a glycosylated protein [110] present in platelets - other cells such as macrophages, dendritic cells, adipocytes, muscle and some types of endothelial cells. While CD36 is a cell receptor for *P. falciparum*-infected erythrocytes [111, 112] there is evidence for other interactions, as antibodies to CD36 did not inhibit interactions with all isolates [95, 113]. The complement receptor gC1qR/HABP1/p32 on both endothelial cells and platelets has been shown to support an interaction with infected RBC’s and supports platelet mediated clumping of infected RBC’s although the parasite ligand is not known [113]. PECAM-1 was also shown to be an endothelial receptor for infected RBC’s [114] and as this is also expressed on the platelet surface it is likely to mediate an interaction with platelets as well.

**Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).** Some strains of *falciparum* malaria parasites induce the formation of small membrane protrusions known as knobs on erythrocytes. These knobs have been identified as the site of contact with endothelial cells and high molecular weight malarial proteins expressed on these knobs mediate this interaction [115-117]. PfEMP1 was subsequently identified as the knob protein that binds to CD36 [118] but also to ICAM-1 and VCAM-1 and it contains a number of different binding domains. PfEMP1 contains two different modules, the Duffy binding-like domain (DBL) of which there are six and the cysteine-rich inter-domain regions (CIDR) of which there are three [119]. The CD36 binding domain has been localized to one of the CIDR’s, CIDRα. A C-terminal 166 amino acid sequence appears to be responsible for the interaction with CD36 and that amino acids 106-166 appear to be especially important [120]. The region of CD36 that binds to PfEMP1 has been located to the region between amino acids 139-184 [121]. While PfEMP1 can directly bind
to CD36 and a number of CD36 ligands can induce platelet aggregation there is no evidence that PfEMP1 triggers platelet activation. However, \textit{P. falciparum} does trigger clumping of infected erythrocytes that is mediated by platelets in a CD36-dependent manner [95] and thus it is possible that this may be due to PfEMP1-CD36 mediated platelet activation.

### 3.2. Role of the endothelium

The endothelium plays an important role in the pathogenesis of malaria. The clumped RBC’s bind to the endothelium and can ultimately occlude smaller blood vessels, especially in the brain. Activated endothelium is a key component of cerebral malaria and has been shown to occur in children [122]. Overproduction of cytokines plays a major role in the activation of the endothelium [123, 124]. One of the key cytokines involved is TNF, which is produced by macrophages in response to malaria antigens [125], possibly acting on TNFR2 [126]. Platelets play a significant role in the destruction of TNF-activated endothelial cells [127-129] while TGF\(_{\beta}\) released from activated platelets can kill TNF-activated endothelial cells [130].

A recent model has been proposed that draws together many of these observations in malaria (Figure 2). Activated endothelial cells secrete high molecular weight vWF, which form strings under high shear. Platelets bind to these strings, which also bind to the activated endothelial cells. Infected RBCs can then in turn bind to the immobilised platelets ultimately occluding the blood vessel which if in the cerebral micro-circulation leads to cerebral malaria [131].

![Figure 2](image)

**Figure 2.** Platelets mediate plasmodium-infected red blood cells binding to the endothelium by GPIb binding to von Willebrand factor (vWF) strings on the endothelium and CD36 binding to \textit{Plasmodium falciparum} erythrocyte membrane protein 1 (PfEMP1) on the red blood cell.

**Platelets as a double-edged sword.** The role of platelets in malaria is complex. On one hand platelet activation is critical in mediating the binding of infected RBCs to the endothelium and subsequent aggregate formation that is cause of cerebral malaria and animal studies suggest that blocking platelet function in mice is beneficial [124, 132, 133]. On the other hand platelets as part of the innate immune system play an important role in mediating the initial immune
response to infection. Studies suggest that platelets play a beneficial role in malaria [134, 135] and mice rendered thrombocytopenic prior to infection had a much higher mortality rate compared with normal mice and thrombocytopenia only occurred in normal rats and not in splenectomised although mortality was much higher in splenectomised rats [134, 136]. Platelets also have been shown to be cytotoxic to plasmodium [137] and that platelet factor 4 (CXCL4) plays a key role in mediating this cytotoxicity [138, 139].

3.3. Other parasites

Schistosomes are trematodes and a major pathogen that causes over 200 million cases of schistosomiasis per year. Thrombocytopenia is a common symptom of infection with Schistosoma mansoni primarily due to platelets gathering in the spleen. There is also an increase in vWF and an increase in MPV [140]. Induction of thrombocytopenia prior to infection has been shown to significantly increase S. mansoni growth and platelets have been shown to bind to and kill the schistosomes [141, 142]. It appears that the cytotoxicity of platelets is enhanced significantly by factors secreted from immune cells such as interferon, tumour necrosis factor and IL-6 [143].

Trypanosomatids are unicellular parasites with a single flagellum and there are two clinically relevant genera. Genus Trypanosoma has two major pathogenic species: T. brucei which is transmitted by the Tsetse fly and causes African sleeping sickness (a neurological disorder) [144] and T. cruzi which is transmitted by triatomine bugs and causes Chagas disease (a cardiac disease) [145]. Genus Leishmania contains a large number of species that cause leishmaniasis in humans and are transmitted by sandflies. T. cruzi infection of mice causes thrombocytopenia [146]. Chagas disease is associated with thromboembolism leading to stroke [145] and interestingly pentamidine which is often used to treat Chagas disease is also an anti-platelet agent (GPIIb/IIIa antagonist) [147] and T. cruzi binds fibronectin which could facilitate an interaction with platelets [148]. Trans-sialidase secreted from the trypanosome has been implicated in Chagas-associated thrombocytopenia as it cleaves sialic acid residues from platelets, which are then cleared from the circulation by Kupffer cells [149]. Kala Azar, a form of leshmaniasis is associated with thrombocytopenia and DIC [150]. In dogs with leshmaniasis there is evidence of an immune mediated thrombocytopenia [151].

4. Conclusions

It is clear that platelets are a key component of the innate immune system where they are the initial responders to infection. They appear to respond to the full range of pathogens including bacteria, parasites and viruses. Thus, thrombocytopenia is a characteristic symptom of infection by any organism. The response to bacteria infection is the best studied and a key role of the platelets is the secretion of anti-microbial peptides that as their name implies kill bacteria. While there is evidence that this also occurs with parasites it may not be true of viruses as they are not cells. There are what appear to be conflicting data on the role of platelets in infection. On one hand severe thrombocytopenia is associated with poor outcome suggesting that platelet activation is important in pathogenesis. On the other hand thrombocytopenic animals are more likely to have a poor outcome suggesting that platelets prevent the disease.
These conflicting data can be resolved in a model where platelets have a dual role. Upon initial exposure to a pathogen there is a decline in platelet number due to the initial immune response. Platelets are activated and bind the pathogen. This then results in pathogen killing or at least clearance of the platelet-pathogen complex from the circulation. If that works then it is the end of the story. The pathogen is ultimately cleared and the disease resolves. However, sometimes platelets fail to clear the pathogen or pathogen replication exceeds the clearance. As a result there is excessive platelet activation that can progress to disseminated intravascular coagulation. Thus, in the early stage of infection platelets are good as they help clear the pathogen, however, in the later stages of infection platelets are bad as they are contributing to the problem.

This then leads to the question of whether platelets are a good target for treating infection. It has been proposed that anti-platelet agents may not be wise in patients with malaria since they are protective [152]. However, it is important to appreciate the stage of the disease. During the early stages of an infection an anti-platelet agent would be undesirable, as it would inhibit the immune functions of the platelets. However, as the disease progresses towards DIC an anti-platelet agent would be desirable as at this point platelets are now part of the problem and their excessive activation must be contained. While conventional anti-platelet agents may be useful in a patient with VHF or DIC this may not be advisable. The result may be that platelet number is preserved but the price paid would be platelet function, which in VHF would exacerbate the bleeding problems. Thus, a better approach may be targeting the platelet receptors that mediate the interactions with the pathogen. This would prevent platelet activation while maintaining platelet function. While some of these targets are likely to be pathogen specific a good target may be FcγRIIa. It has been shown to be critical in bacteria-induced platelet activation but also appears to play a role in some viral infections.

**Author details**

Ana Lopez Alonso and Dermot Cox*

*Address all correspondence to: dcox@rcsi.ie

Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

**References**

[1] Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. Journal of Thrombosis and Haemostasis. 2011; 9: 1097-107.

[2] Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11: 264-74.
[3] Keogh B, Parker AE. Toll-like receptors as targets for immune disorders. Trends in Pharmacological Sciences. 2011; 32: 435-42.

[4] Keane C, Tilley D, Cunningham A, Smolenski A, Kadioglu A, Cox D, Jenkinson HF, Kerrigan SW. Invasive Streptococcus pneumoniae trigger platelet activation via Toll-like receptor 2. J Thrombos Haemost. 2010; 8: 2757-65.

[5] Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature medicine. 2007; 13: 463-9.

[6] Koupenova M, Vitseva O, MacKay CR, Beaulieu LM, Benjamin EJ, Mick E, Kurt-Jones EA, Ravid K, Freedman JE. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. 2014.

[7] Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012; 11: 311-31.

[8] Riaz AH, Tasma BE, Woodman ME, Wooten RM, Worth RG. Human platelets efficiently kill IgG-opsonized E. coli. FEMS Immunology & Medical Microbiology. 2012; 65: 78-83.

[9] Antczak AJ, Vieth JA, Singh N, Worth RG. Internalization of IgG-Coated Targets Results in Activation and Secretion of Soluble CD40 Ligand and RANTES by Human Platelets. Clin Vaccine Immunol. 2011; 18: 210-6.

[10] Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, Higgins J, Visai L, Specziale P, Cox D, Foster TJ. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgRIIa receptor. Mol Microbiol. 2006; 59: 212-30.

[11] Huang Z-Y, Chien P, Indik ZK, Schreiber AD. Human platelet Fc[gamma]RIIA and phagocytes in immune-complex clearance. Molecular Immunology. 2011; 48: 691-6.

[12] Garcia-Vallejo JJ, van Kooyk Y. The physiological role of DC-SIGN: A tale of mice and men. Trends in Immunology. 2013; 34: 482-6.

[13] Hottz ED, Oliveira MF, Nunes PC, Nogueira RM, Valls-de-Souza R, Da Poian AT, Weyrich AS, Zimmerman GA, Bozza PT, Bozza FA. Dengue induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that involve DC-SIGN and caspases. J Thromb Haemost. 2013; 11: 951-62.

[14] Rex S, Beaulieu L, Perlman D, Vitseva O, Blair P, McComb M, Costello C, Freedman J. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost. 2009; 102: 97-110.
[15] Cox D. Bacteria-platelet interactions. *Journal of Thrombosis and Haemostasis*. 2009; 7: 1865-6.

[16] Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. *Nat Rev Microbiol*. 2006; 4: 445-57.

[17] Kerrigan S, Cox D. The Effect of Bacterial Toxins on Platelet Function. In: Kini RM, Clemetson KJ, Markland FS, McLane MA, Morita T, eds. *Toxins and Hemostasis From Bench to Bedside*. Heidelberg: Springer, 2010, 637-51.

[18] Arman M, Krauel K, Tilley DO, Weber C, Cox D, Greinacher A, Kerrigan SW, Watson SP. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3, and platelet factor 4. *Blood*. 2014; 123: 3166-74.

[19] Bosmann M, Ward PA. The inflammatory response in sepsis. *Trends in Immunology*. 2013; 34: 129-36.

[20] Cox D, Salvato M, Zapata J. The Role of Platelets in Viral Hemorrhagic Fevers. *J Bioterr Biodef*. 2013; S12-003.

[21] Harada-Shirado K, Ikeda K, Furukawa M, Sukegawa M, Takahashi H, Shichishima-Nakamura A, Okawara H, Noji H, Kawabata K, Saito S-i, Ohto H, Ogawa K, Takeishi Y. Severe Immune Thrombocytopenia Possibly Elicited by the Anti-influenza Viral Agent Peramivir. *Internal Medicine*. 2014; 53: 2369-71.

[22] Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. *AIDS*. 2011; 25: 2243-8.

[23] Zapata JC, Cox D, Salvato MS. The Role of Platelets in the Pathogenesis of Viral Hemorrhagic Fevers. *PLoS Negl Trop Dis*. 2014; 8: e2858.

[24] Leyssen P, De Clercq E, Neyts J. Perspectives for the treatment of infections with Flaviviridae. *Clin Microbiol Rev*. 2000; 13: 67-82, table of contents.

[25] Ruzek D, Yakimenko VV, Karan LS, Tkachev SE. Omsk haemorrhagic fever. *Lancet*. 2010; 376: 2104-13.

[26] Kyasanur Forest Disease. CDC, 2012.

[27] Scientific working group report on dengue. WHO, 2006.

[28] Dengue - Guidelines for diagnosis, Treatment, prevention and control. Geneva, Switzerland: World Health Organization, 2009.

[29] Gibbons RV, Vaughn DW. Dengue: an escalating problem. *BMJ*. 2002; 324: 1563-6.

[30] Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. *J Clin Virol*. 2003; 27: 1-13.
[31] Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A. 2005; 102: 15259-64.

[32] Schmidt AC. Response to Dengue Fever — The Good, the Bad, and the Ugly? New England Journal of Medicine. 2010; 363: 484-7.

[33] Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007; 104: 9422-7.

[34] Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, Smit JM. Immature dengue virus: a veiled pathogen? PLoS pathogens. 2010; 6: e1000718.

[35] Moi ML, Lim C-K, Takasaki T, Kurane I. Involvement of the Fc[gamma] receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. J Gen Virol. 2010; 91: 103-11.

[36] Hottz ED, Lopes JF, Freitas C, Valls-de-Souza R, Oliveira MF, Bozza MT, Da Poian AT, Weyrich AS, Zimmerman GA, Bozza FA, Bozza PT. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. 2013.

[37] Noisakran S, Onlamoon N, Hsiao H-M, Clark KB, Villinger F, Ansari AA, Perng GC. Infection of bone marrow cells by dengue virus in vivo. Experimental hematology. 2012; 40: 250-9.e4.

[38] Fisher-Hoch SP, Platt GS, Lloyd G, Simpson DI, Neild GH, Barrett AJ. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet. 1983; 2: 1055-8.

[39] Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, Lloyd G, Simpson DI. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis. 1985; 152: 887-94.

[40] McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Towner JS, Nichol ST, Spiropoulou CF. Von Willebrand Factor Is Elevated in Individuals Infected with Sudan Virus and Is Associated with Adverse Clinical Outcomes. Viral Immunol. 2014.

[41] Ekiz F, Gurbuz Y, Basar O, Aytekin G, Ekiz O, Senturk CS, Aktas B, Yilmaz B, Altincbas A, Coban S, Sencan I. Mean platelet volume in the diagnosis and prognosis of Crimean-Congo hemorrhagic fever. Clin Appl Thromb Hemost. 2013; 19: 441-4.

[42] Cui N, Bao X-L, Yang Z-D, Lu Q-B, Hu C-Y, Wang L-Y, Wang B-J, Wang H-Y, Liu K, Yuan C, Fan X-J, Wang Z, Zhang L, Zhang X-A, Hu L-P, Liu W, Cao W-C. Clinical progression and predictors of death in patients with severe fever with thrombocytopenia syndrome in China. Journal of Clinical Virology. 2014; 59: 12-7.

[43] Jin C, Liang M, Ning J, Gu W, Jiang H, Wu W, Zhang F, Li C, Zhang Q, Zhu H, Chen T, Han Y, Zhang W, Zhang S, Wang Q, Sun L, Liu Q, Li J, Wang T, Wei Q, Wang S,
Deng Y, Qin C, Li D. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model. *Proc Natl Acad Sci U S A*. 2012; 109: 10053-8.

[44] Wang M, Wang J, Wang T, Li J, Hui L, Ha X. Thrombocytopenia as a predictor of severe acute kidney injury in patients with Hantaan virus infections. *PLoS One*. 2013; 8: e53236.

[45] Erduran E, Bahadir A, Palanci N, Gedik Y. The treatment of crimean-congo hemorrhagic fever with high-dose methylprednisolone, intravenous immunoglobulin, and fresh frozen plasma. *J Pediatr Hematol Oncol*. 2013; 35: e19-24.

[46] van Mirre E, Teeling JL, van der Meer JWM, Bleeker WK, Hack CE. Monomeric IgG in Intravenous Ig Preparations Is a Functional Antagonist of Fc\(\gamma\)RII and Fc\(\gamma\)RIIIb. *J Immunol*. 2004; 173: 332-9.

[47] Cummins D. Arenaviral haemorrhagic fevers. *Blood Rev*. 1991; 5: 129-37.

[48] Loria GD, Romagnoli PA, Moseley NB, Rucavado A, Altman JD. Platelets support a protective immune response to LCMV by preventing splenic necrosis. *Blood*. 2013; 121: 940-50.

[49] Gómez RM, Schattner M. Arenaviruses bite the “dust”. 2013.

[50] Schattner M, Rivadeneyra L, Pozner R, Gómez R. Pathogenic Mechanisms Involved in the Hematological Alterations of Arenavirus-induced Hemorrhagic Fevers. *Viruses*. 2013; 5: 340-51.

[51] Negrotto S, Jaquenod de Giusti C, Rivadeneyra L, Ure AE, Mena HA, Schattner M, Gomez RM. Platelets interact with Coxsackieviruses B and have a critical role in the pathogenesis of virus-induced myocarditis. *J Thromb Haemost*. 2014.

[52] Assinger A, Kral JB, Yaiw KC, Schrottmaier WC, Kurzejamska E, Wang Y, Mohammad A-A, Religa P, Rahbar A, Schabbauer G, Butler LM, Söderberg-Naucler C. Human Cytomegalovirus–Platelet Interaction Triggers Toll-Like Receptor 2–Dependent Proinflammatory and Proangiogenic Responses. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2014; 34: 801-9.

[53] Solomon Tsegaye T, GnirSZ K, Rahe-Meyer N, Kiene M, Kramer-Kuhl A, Behrens G, Munch J, Pohlmann S. Platelet activation suppresses HIV-1 infection of T cells. *Retrovirology*. 2013; 10: 48.

[54] Damien P, Cognasse F, Lucht F, Suy F, Pozzetto B, Garraud O, Hamzeh-Cognasse H. Highly Active Antiretroviral Therapy Alters Inflammation Linked to Platelet Cytokines in HIV-1–Infected Patients. *Journal of Infectious Diseases*. 2013; 208: 868-70.

[55] Boilard E, Paré G, Rousseau M, Cloutier N, Dubuc I, Lévesque T, Borgeat P, Flamand L. Influenza virus H1N1 activates platelets through Fc\(\gamma\)RIIA signaling and thrombin generation. 2014.
[56] Beck Z, Jagodzinski LL, Eller MA, Thelian D, Matyas GR, Kunz AN, Alving CR. Platelets and Erythrocyte-Bound Platelets Bind Infectious HIV-1 in Plasma of Chronically Infected Patients. *PLoS ONE*. 2013; 8: e81002.

[57] Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, Geier M, Stewart EA, Eisemann J, Steinkasserer A, Suzuki-Inoue K, Fuller GL, Pearce AC, Watson SP, Hoxie JA, Baribaud F, Pohlmann S. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. *J Virol*. 2006; 80: 8951-60.

[58] Jin YY, Yu XN, Qu ZY, Zhang AA, Xing YL, Jiang LX, Shang L, Wang YC. Adenovirus type 3 induces platelet activation in vitro. *Mol Med Rep*. 2014; 9: 370-4.

[59] Dou J, Lou Y, Wu J, Lu Y, Jin Y. Thrombocytopenia in patients with hepatitis B virus-related chronic hepatitis: Evaluation of the immature platelet fraction. *Platelets*. 2014; 25: 399-404.

[60] Nguyen T, Kyle UG, Jaimon N, Tcharmtchi MH, Coss-Bu JA, Lam F, Teruya J, Loftis L. Coinfection with Staphylococcus aureus increases risk of severe coagulopathy in critically ill children with influenza A (H1N1) virus infection. *Crit Care Med*. 2012; 40: 3246-50.

[61] Metcalf Pate KA, Lyons CE, Dorsey JL, Shirk EN, Queen SE, Adams RJ, Gama L, Morrell CN, Mankowski JL. Platelet Activation and Platelet-Monocyte Aggregate Formation Contribute to Decreased Platelet Count During Acute Simian Immunodeficiency Virus Infection in Pig-tailed Macaques. *Journal of Infectious Diseases*. 2013; 208: 874-83.

[62] Lopez-Delgado JC, Rovira A, Esteve F, Rico N, Manez Mendiluce R, Ballus Noguera J, Berrade J. Thrombocytopenia as a mortality risk factor in acute respiratory failure in H1N1 influenza. *Swiss Med Wkly*. 2013; 143: w13788.

[63] Singh MV, Davidson DC, Jackson JW, Singh VB, Silva J, Ramirez SH, Maggirwar SB. Characterization of Platelet–Monocyte Complexes in HIV-1–Infected Individuals: Possible Role in HIV-Associated Neuroinflammation. *The Journal of Immunology*. 2014; 192: 4674-84.

[64] Armstrong SM, Darwish I, Lee WL. Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection. *Virulence*. 2013; 4: 537-42.

[65] Davidson D, Jackson J, Maggirwar S. Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation? *Journal of Neuroinflammation*. 2013; 10: 144.

[66] Bethel-Brown C, Yao H, Hu G, Buch S. Platelet-derived growth factor (PDGF)-BB-mediated induction of monocyte chemoattractant protein 1 in human astrocytes: implications for HIV-associated neuroinflammation. *J Neuroinflammation*. 2012; 9: 262.

[67] O’Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS. Aspirin attenuates platelet activation and
immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. *J Acquir Immune Defic Syndr.* 2013; 63: 280-8.

[68] Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. *Thromb Res.* 2012; 129: 301-8.

[69] Ronsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR. Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. *PLoS One.* 2013; 8: e65182.

[70] Zetterberg E, Neuhaus J, Baker JV, Somboonwit C, Llibre JM, Palfreeman A, Chini M, Lundgren JD, Group ISS. Platelet count kinetics following interruption of antiretroviral treatment. *AIDS.* 2013; 27: 59-68.

[71] Wang J, Zhang W, Nardi MA, Li Z. HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia. *Journal of Thrombosis and Haemostasis.* 2011; 9: 562-73.

[72] Jenne Craig N, Wong Connie HY, Zemp Franz J, McDonald B, Rahman Masmudur M, Forsyth Peter A, McFadden G, Kubes P. Neutrophils Recruited to Sites of Infection Protect from Virus Challenge by Releasing Neutrophil Extracellular Traps. *Cell Host & Microbe.* 2013; 13: 169-80.

[73] Kondo R, Yano H, Nakashima O, Tanikawa K, Nomura Y, Kage M. Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C. *J Gastroenterol.* 2013; 48: 526-34.

[74] Metcalf Pate KA, Lyons CE, Dorsey JL, Queen SE, Adams RJ, Morrell CN, Mankowski JL. TGFbeta-Mediated Downregulation of Thrombopoietin Is Associated With Platelet Decline in Asymptomatic SIV Infection. *J Acquir Immune Defic Syndr.* 2014; 65: 510-6.

[75] Sridharan A, Chen Q, Tang KF, Ooi EE, Hibberd ML, Chen J. Inhibition of Megakaryocyte Development in the Bone Marrow Underlies Dengue Virus-Induced Thrombocytopenia in Humanized Mice. *Journal of Virology.* 2013; 87: 11648-58.

[76] Clark KB, Noisakran S, Onlamoon N, Hsiao HM, Roback J, Villinger F, Ansari AA, Perng GC. Multiploid CD61+ Cells Are the Pre-Dominant Cell Lineage Infected during Acute Dengue Virus Infection in Bone Marrow. *PLoS One.* 2012; 7: e52902.

[77] Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, MingoZZi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, Guidotti LG. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. *Proceedings of the National Academy of Sciences.* 2012; 109: E2165–E72.

[78] Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. *Journal of Hepatology.* 2013; 59: 1135-8.
[79] Renshaw AA, Drago B, Toraya N, Gould EW. Respiratory syncytial virus infection is strongly correlated with decreased mean platelet volume. *International Journal of Infectious Diseases*. 2013; 17: e678-e80.

[80] Mete E, Akelma AZ, Cizmeci MN, Bozkaya D, Kanburoglu MK. Decreased mean platelet volume in children with acute rotavirus gastroenteritis. *Platelets*. 2014; 25: 51-4.

[81] Mena A, Meijide H, Vazquez P, Castro A, Lopez S, Bello L, Serrano J, Balinas J, Pedreira JD. HIV increases mean platelet volume during asymptomatic HIV infection in treatment-naive patients. *J Acquir Immune Defic Syndr*. 2011; 57: e112-3.

[82] Freeman ML, Burkum CE, Lanzer KG, Roberts AD, Pinkevych M, Itakura A, Kummer LW, Szaba FM, Davenport MP, McCarty OJ, Woodland DL, Smiley ST, Blackman MA. Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. *J Autoimmun*. 2013; 42: 71-9.

[83] Schlenke P. Pathogen Inactivation Technologies for Cellular Blood Components: an Update. *Transfusion Medicine and Hemotherapy*. 2014; 41: 309-25.

[84] Lozano M, Cid J. Pathogen inactivation: coming of age. *Curr Opin Hematol*. 2013; 20: 540-5.

[85] Seltzam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. *Br J Haematol*. 2013; 162: 442-54.

[86] Prowse CV. Component pathogen inactivation: a critical review. *Vox Sang*. 2013; 104: 183-99.

[87] Kerrigan SW, Clarke N, Loughman A, Meade G, Foster TJ, Cox D. Molecular basis for *Staphylococcus aureus*-mediated platelet aggregate formation under arterial shear in vitro. *Arterioscler Thromb Vasc Biol*. 2008; 28: 335-40.

[88] Cox D, McConkey S. The role of platelets in the pathogenesis of cerebral malaria. *Cellular and Molecular Life Sciences*. 2010; 67: 557-68.

[89] Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. *Lancet Neurol*. 2005; 4: 827-40.

[90] Angchaisuksiri P. Coagulopathy in malaria. *Thromb Res*. 2014; 133: 5-9.

[91] Muley A, Lakhani J, Bhirud S, Patel A. Thrombocytopenia in Plasmodium vivax Malaria: How Significant? *J Trop Med*. 2014; 2014: 567469.

[92] Patel U, Gandhi G, Friedman S, Niranjan S. Thrombocytopenia in malaria. *J Natl Med Assoc*. 2004; 96: 1212-4.

[93] Erhart LM, Yingyuen K, Chuanak N, Buathong N, Laoboonchai A, Miller RS, Meshnick SR, Gasser RA, Jr., Wongsrichanalai C. Hematologic and clinical indices of malaria in a semi-immune population of western Thailand. *Am J Trop Med Hyg*. 2004; 70: 8-14.
[94] Rogier C, Gerardin P, Imbert P. Thrombocytopenia is predictive of lethality in severe childhood falciparum malaria. *Arch Dis Child*. 2004; 89: 795-a-6.

[95] Pain A, Ferguson DJ, Kai O, Urban BC, Lowe B, Marsh K, Roberts DJ. Platelet-mediated clumping of *Plasmodium falciparum*-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. *Proc Natl Acad Sci U S A*. 2001; 98: 1805-10.

[96] Gerardin P, Rogier C, Ka AS, Jouvencel P, Brousse V, Imbert P. Prognostic value of thrombocytopenia in African children with falciparum malaria. *Am J Trop Med Hyg*. 2002; 66: 686-91.

[97] Facer CA, Theodoridou A. Elevated plasma levels of P-selectin (GMP-140/CD62P) in patients with *Plasmodium falciparum* malaria. *Microbiol Immunol*. 1994; 38: 727-31.

[98] Scott CS, Van Zyl D, Ho E, Ruivo L, Mendelow B, Coetzee TL. Thrombocytopenia in patients with malaria: automated analysis of optical platelet counts and platelet clumps with the Cell Dyn CD4000 analyser. *Clin Lab Haematol*. 2002; 24: 295-302.

[99] Chang WL, Li J, Sun G, Chen HL, Specian RD, Berney SM, Granger DN, van der Heyde HC. P-selectin contributes to severe experimental malaria but is not required for leukocyte adhesion to brain microvasculature. *Infect Immun*. 2003; 71: 1911-8.

[100] Combes V, Rosenkranz AR, Redard M, Pizzolato G, Lepidi H, Vestweber D, Maya-das TN, Grau GE. Pathogenic role of P-selectin in experimental cerebral malaria: importance of the endothelial compartment. *Am J Pathol*. 2004; 164: 781-6.

[101] Adam C, Geniteau M, Gougerot-Pocidalo M, Verroust P, Lebras J, Gibert C, Morel-Maroger L. Cryoglobulins, circulating immune complexes, and complement activation in cerebral malaria. *Infect Immun*. 1981; 31: 530-5.

[102] Rock G, Clark W, Sternbach M, Kolajova M, McLaine P. Haemolytic uraemic syndrome is an immune-mediated disease: role of anti-CD36 antibodies. *Br J Haematol*. 2005; 131: 247-52.

[103] Ockenhouse CF, Magowan C, Chulay JD. Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. *J Clin Invest*. 1989; 84: 468-75.

[104] Kelton JG, Keystone J, Moore J, Denomme G, Tozman E, Glynn M, Neame PB, Gauldie J, Jensen J. Immune-mediated thrombocytopenia of malaria. *J Clin Invest*. 1983; 71: 832-6.

[105] Yamaguchi S, Kubota T, Yamagishi T, Okamoto K, Izumi T, Takada M, Kanou S, Suzuki M, Tsuchiya J, Naruse T. Severe thrombocytopenia suggesting immunological mechanisms in two cases of vivax malaria. *American Journal of Hematology*. 1997; 56: 183-6.
[106] Cooke GS, Aucan C, Walley AJ, Segal S, Greenwood BM, Kwiatkowski DP, Hill AVS. Association Of Fcγ Receptor IIa (CD32) Polymorphism With Severe Malaria In West Africa. *Am J Trop Med Hyg*. 2003; 69: 565-8.

[107] Seka-Seka J, Brouh Y, Yapo-Crezoit AC, Atseye NH. The role of serum immunoglobulin E in the pathogenesis of Plasmodium falciparum malaria in Ivorian children. *Scand J Immunol*. 2004; 59: 228-30.

[108] Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, Allasia C, Cataldo C, Taylor TE, Molyneux ME. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. *J Infect Dis*. 2003; 187: 461-6.

[109] Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, Milner D, Kamiza S, Molyneux M, Taylor TE. The neuropathology of fatal cerebral malaria in malawian children. *Am J Pathol*. 2011; 178: 2146-58.

[110] Tandon NN, Lipsky RH, Burgess WH, Jamieson GA. Isolation and characterization of platelet glycoprotein IV (CD36). *J Biol Chem*. 1989; 264: 7570-5.

[111] Barnwell JW, Asch AS, Nachman RL, Yamaya M, Aikawa M, Ingravallo P. A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. *J Clin Invest*. 1989; 84: 765-72.

[112] Ockenhouse CF, Tandon NN, Magowan C, Jamieson GA, Chulay JD. Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. *Science*. 1989; 243: 1469-71.

[113] Biswas AK, Hafiz A, Banerjee B, Kim KS, Datta K, Chitnis CE. Plasmodium falciparum uses gC1qR/HABP1/p32 as a receptor to bind to vascular endothelium and for platelet-mediated clumping. *PLoS pathogens*. 2007; 3: 1271-80.

[114] Treutiger CJ, Heddini A, Fernandez V, Muller WA, Wahlgren M. PECAM-1/CD31, an endothelial receptor for binding Plasmodium falciparum-infected erythrocytes. *Nature medicine*. 1997; 3: 1405-8.

[115] Kilejian A. Characterization of a protein correlated with the production of knob-like protrusions on membranes of erythrocytes infected with Plasmodium falciparum. *Proc Natl Acad Sci U S A*. 1979; 76: 4650-3.

[116] Leech JH, Barnwell JW, Aikawa M, Miller LH, Howard RJ. Plasmodium falciparum malaria: association of knobs on the surface of infected erythrocytes with a histidine-rich protein and the erythrocyte skeleton. *J Cell Biol*. 1984; 98: 1256-64.

[117] Aley SB, Sherwood JA, Howard RJ. Knob-positive and knob-negative Plasmodium falciparum differ in expression of a strain-specific malarial antigen on the surface of infected erythrocytes. *J Exp Med*. 1984; 160: 1585-90.

[118] Baruch DI, Gormley JA, Ma C, Howard RJ, Pasloske BL. Plasmodium falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for adherence to
CD36, thrombospondin, and intercellular adhesion molecule 1. *PNAS*. 1996; 93: 3497-502.

[119] Smith J, Kyes S, Craig A, Fagan T, Hudson-Taylor D, Miller L, Baruch D, Newbold C. Analysis of adhesive domains from the A4VAR Plasmodium falciparum erythrocyte membrane protein-1 identifies a CD36 binding domain. *Mol Biochem Parasitol*. 1998; 97: 133-48.

[120] Mo M, Lee HC, Kotaka M, Niang M, Gao X, Iyer JK, Lescar J, Preiser P. The C-terminal segment of the cysteine-rich interdomain of Plasmodium falciparum erythrocyte membrane protein 1 determines CD36 binding and elicits antibodies that inhibit adhesion of parasite-infected erythrocytes. *Infect Immun*. 2008; 76: 1837-47.

[121] Baruch DI, Ma XC, Pasloske B, Howard RJ, Miller LH. CD36 Peptides That Block Cytoskeletal Change Define the CD36 Binding Region for Plasmodium falciparum-Infected Erythrocytes. *Blood*. 1999; 94: 2121-7.

[122] Hollestelle MJ, Donkor C, Mantey EA, Chakravorty SJ, Craig A, Akoto AO, O'Donnell J, van Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. *British Journal of Haematology*. 2006; 133: 562-9.

[123] Grau GE, Tacchini-Cottier F, Vesin C, Milon G, Lou JN, Piguet PF, Juillard P. TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction. *Eur Cytokine Netw*. 1993; 4: 415-9.

[124] van der Heyde HC, Gramaglia I, Sun G, Woods C. Platelet depletion by anti-CD41 (αIIb) mAb injection early but not late in the course of disease protects against Plasmodium berghei pathogenesis by altering the levels of pathogenic cytokines. *Blood*. 2005; 105: 1956-63.

[125] Bate CA, Taverne J, Kwiatkowski D, Playfair JH. Phospholipids coupled to a carrier induce IgG antibody that blocks tumour necrosis factor induction by toxic malaria antigens. *Immunology*. 1993; 79: 138-45.

[126] Piguet PF, Kan CD, Vesin C. Role of the tumor necrosis factor receptor 2 (TNFR2) in cerebral malaria in mice. *Lab Invest*. 2002; 82: 1155-66.

[127] Lou J, Donati YR, Juillard P, Giroud C, Vesin C, Mili N, Grau GE. Platelets play an important role in TNF-induced microvascular endothelial cell pathology. *Am J Pathol*. 1997; 151: 1397-405.

[128] Wassmer SC, Lepolard C, Traore B, Pouvelle B, Gysin J, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. *J Infect Dis*. 2004; 189: 180-9.

[129] Grau G, Tacchini-Cottier F, Vesin C, Milon G, Lou J, Piguet P, Juillard P. TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/ICAM-1 interaction. *Eur Cytokine Netw*. 1993; 4: 415-9.
Wassmer SC, de Souza JB, Frere C, Candal FJ, Juhan-Vague I, Grau GE. TGF-beta1 released from activated platelets can induce TNF-stimulated human brain endothelium apoptosis: a new mechanism for microvascular lesion during cerebral malaria. *J Immunol.* 2006; 176: 1180-4.

Bridges DJ, Bunn J, van Mourik JA, Grau G, Preston RJS, Molyneux M, Combes V, O'Donnell JS, de Laat B, Craig A. Rapid activation of endothelial cells enables *Plasmodium falciparum* adhesion to platelet-decorated von Willebrand factor strings. *Blood.* 2010; 115: 1472-4.

Sun G, Chang WL, Li J, Berney SM, Kimpel D, van der Heyde HC. Inhibition of platelet adherence to brain microvasculature protects against severe *Plasmodium berghei* malaria. *Infect Immun.* 2003; 71: 6553-61.

Wassmer SC, Combes V, Candal FJ, Juhan-Vague I, Grau GE. Platelets potentiate brain endothelial alterations induced by *Plasmodium falciparum*. *Infect Immun.* 2006; 74: 645-53.

Polack B, Delolme F, Peyron F. Protective role of platelets in chronic (Balb/C) and acute (CBA/J) *Plasmodium berghei* murine malaria. *Haemostasis.* 1997; 27: 278-85.

Wassmer SC, Taylor T, MacLennan CA, Kanjala M, Mukaka M, Molyneux ME, Grau GE. Platelet-Induced Clumping of *Plasmodium falciparum*-Infected Erythrocytes from Malawian Patients with Cerebral Malaria: Possible Modulation In Vivo by Thrombocytopenia. *The Journal of Infectious Diseases.* 2008; 197: 72-8.

Aggrey AA, Srivastava K, Ture S, Field DJ, Morrell CN. Platelet induction of the acute-phase response is protective in murine experimental cerebral malaria. *J Immunol.* 2013; 190: 4685-91.

McMorran BJ, Marshall VM, de Graaf C, Drysdale KE, Shabbar M, Smyth GK, Corbin JE, Alexander WS, Foote SJ. Platelets Kill Intraerythrocytic Malarial Parasites and Mediate Survival to Infection. *Science.* 2009; 323: 797-800.

Srivastava K, Cockburn IA, Swaim A, Thompson LE, Tripathi A, Fletcher CA, Shirk EM, Sun H, Kowalska MA, Fox-Talbot K, Sullivan D, Zavala F, Morrell CN. Platelet Factor 4 Mediates Inflammation in Experimental Cerebral Malaria. *Cell Host & Microbe.* 2008; 4: 179-87.

McMorran BJ, Wieczorski L, Drysdale KE, Chan JA, Huang HM, Smith C, Mitiku C, Beeson JG, Burgio G, Foote SJ. Platelet factor 4 and Duffy antigen required for platelet killing of *Plasmodium falciparum*. *Science.* 2012; 338: 1348-51.

Correia MC, Domingues AL, Lacerda HR, Santos EM, Machado CG, Hora V, Neves MA, Brito A, Coelho MR, Silva JL. Platelet function and the von Willebrand factor antigen in the hepatosplenic form of schistosomiasis mansoni. *Trans R Soc Trop Med Hyg.* 2009; 103: 1053-8.
[141] Stanley RG, Ngaiza JR, Wambayi E, Lewis J, Doenhoff MJ. Platelets as an innate defence mechanism against Schistosoma mansoni infections in mice. *Parasite Immunology*. 2003; 25: 467-73.

[142] Stanley R, Ngaiza J, Atieno E, Jell G, Francklow K, Jackson C, Parry H, Doenhoff M. Immune-dependent thrombocytopenia in mice infected with *Schistosoma mansoni*. *Parasitology*. 2003; 126: 225-9.

[143] Da’dara AA, Skelly PJ. Schistosomes versus platelets. *Thromb Res*. 2014.

[144] Kennedy PGE. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). *The Lancet Neurology*. 2013; 12: 186-94.

[145] Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL, Council on Chagas Disease of the Interamerican Society of C. Chagas disease: an overview of clinical and epidemiological aspects. *J Am Coll Cardiol*. 2013; 62: 767-76.

[146] da Silva RV, Malvezi AD, Augusto Lda S, Kian D, Tatakahe VL, Yamauchi LM, Yamada-Ogatta SF, Rizzo LV, Schenkm an S, Pinge-Filho P. Oral exposure to Phytomonas serpens attenuates thrombocytopenia and leukopenia during acute infection with Trypanosoma cruzi. *PLoS One*. 2013; 8: e68299.

[147] Cox D, Motoyama Y, Seki J, Aoki T, Dohi M, Yoshida K. Pentamidine: a non-peptide GPIIb/IIIa antagonist—in vitro studies on platelets from humans and other species. *Thrombosis and Haemostasis*. 1992; 68: 731-6.

[148] Cox D, Uga S, Motoyama Y, Yoshida K. Characterization of the fibronectin binding properties of *Trypanosoma cruzi* epimastigotes. *J Protozool Res*. 1992; 2: 149-57.

[149] Tribulatti MV, Mucci J, Van Rooijen N, Leguizamon MS, Campetella O. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas’ disease by reducing the platelet sialic acid contents. *Infect Immun*. 2005; 73: 201-7.

[150] Varma N, Naseem S. Hematologic changes in visceral leishmaniasis/kala azar. *Indian J Hematol Blood Transfus*. 2010; 26: 78-82.

[151] Cortese L, Terrazzano G, Piantedosi D, Sica M, Prisco M, Ruggiero G, Ciaramella P. Prevalence of anti-platelet antibodies in dogs naturally co-infected by Leishmania infantum and Ehrlichia canis. *Vet J*. 2011; 188: 118-21.

[152] Greenbaum DC, FitzGerald GA. Platelets, Pyrexia, and Plasmodia. *N Engl J Med*. 2009; 361: 526-8.
